The deal size was increased to $350M from $250M and priced below last closing price of $46.84. JPMorgan, Morgan Stanley, Guggenheim and Cantor Fitzgerald are acting as joint book running managers for the offering.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics Suspends ATM Prospectus with Jefferies
- Cidara Therapeutics price target raised to $68 from $50 at Guggenheim
- Cidara Therapeutics price target raised to $75 from $35 at RBC Capital
- Why Is Cidara Therapeutics Stock (CDTX) Up 80% Today?
- Cidara Therapeutics announces $250M common stock offering